All
Calquence Linked to Fewer Heart-Related, Other Toxicities in Patients With CLL Than Imbruvica
January 7th 2022Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.
Expert Explores the Relationship Between Down Syndrome and Leukemia
January 6th 2022In this episode of the “Cancer Horizons” podcast, an expert unpacks cancer risks for individuals with Down syndrome and analyzes the results of a recent study about mortality risks for childhood survivors later in life.
Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’
January 6th 2022An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
Trial Underway to Assess Efficacy of Novel Radiopharmaceutical Drug in Neuroendocrine Tumors
January 5th 2022The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.
Survival With Immunotherapy in Common Brain Tumor Subtype May Be Predicted by a Biomarker
January 3rd 2022Patients with a common brain tumor subtype that expresses ERK1/2 activation may obtain a greater survival benefit with PD-1 immunotherapy, although research needs to confirm whether this can be observed in all patients.